Gab122
08-29-2016, 04:29 AM
Article dated July 2016
Gist of it: (conclusion of study copied below.) very Interesting that it mentions ANCA increase among "those treated with rituximab." I'm going to ask about this.
"Conclusion
The association of an increase in PR3-ANCA level with the risk of subsequent relapse is partially affected by the PR3-ANCA detection methodology, disease phenotype, and remission induction treatment. An increase in PR3-ANCA level during complete remission conveys an increased risk of relapse, particularly severe relapse, among patients with renal involvement or alveolar hemorrhage and those treated with rituximab. Serial measurements of PR3-ANCA may be informative in this subset of patients, but the risk of relapse must be weighed carefully against the risks associated with therapy."
Link to article:
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 - Fussner - 2016 - Arthritis & Rheumatology - Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/art.39637/abstract?systemMessage=Wiley+Online+Library+will+b e+unavailable+on+Saturday+3rd+September+2016+at+08 .30+BST/+03:30+EDT/+15:30+SGT+for+5+hours+and+Sunday+4th+September+at +10:00+BST/+05:00+EST/+17:00+SGT+for+1+hour++for+essential+maintenance.+ Apologies+for+the+inconvenience)
Gist of it: (conclusion of study copied below.) very Interesting that it mentions ANCA increase among "those treated with rituximab." I'm going to ask about this.
"Conclusion
The association of an increase in PR3-ANCA level with the risk of subsequent relapse is partially affected by the PR3-ANCA detection methodology, disease phenotype, and remission induction treatment. An increase in PR3-ANCA level during complete remission conveys an increased risk of relapse, particularly severe relapse, among patients with renal involvement or alveolar hemorrhage and those treated with rituximab. Serial measurements of PR3-ANCA may be informative in this subset of patients, but the risk of relapse must be weighed carefully against the risks associated with therapy."
Link to article:
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 - Fussner - 2016 - Arthritis & Rheumatology - Wiley Online Library (http://onlinelibrary.wiley.com/doi/10.1002/art.39637/abstract?systemMessage=Wiley+Online+Library+will+b e+unavailable+on+Saturday+3rd+September+2016+at+08 .30+BST/+03:30+EDT/+15:30+SGT+for+5+hours+and+Sunday+4th+September+at +10:00+BST/+05:00+EST/+17:00+SGT+for+1+hour++for+essential+maintenance.+ Apologies+for+the+inconvenience)